How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,379 results for

Cushing Response

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Mifepristone in Children With Refractory Cushing's Disease

Cushing's Disease The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01925092 Recruitment Status : Withdrawn (Lack of enrollment) First Posted : August 19, 2013 Last Update Posted : August 4, 2014 Sponsor: Corcept Therapeutics Collaborator: Eunice Kennedy Shriver National Institute of Child Health and Human (...) Development (NICHD) Information provided by (Responsible Party): Corcept Therapeutics Study Details Study Description Go to Brief Summary: Study objectives are to obtain safety, pharmacokinetic, and pharmacodynamic data on the effect of mifepristone on glucose metabolism, body weight and the growth-hormone-IGF in children with refractory Cushing's disease. Condition or disease Intervention/treatment Phase Cushing's Disease Drug: mifepristone Phase 3 Detailed Description: The study is being done to examine

2013 Clinical Trials

122. Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

). Please remove one or more studies before adding more. Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01915303 Recruitment Status : Active, not recruiting First Posted : August 2, 2013 Last Update (...) Posted : February 11, 2019 Sponsor: Novartis Pharmaceuticals Information provided by (Responsible Party): Novartis ( Novartis Pharmaceuticals ) Study Details Study Description Go to Brief Summary: This study is to assess whether pasireotide alone and combined with cabergoline will give reliefs on patients with recurrent, persistent and newly diagnosed Cushing's disease. The study will also assess study drug safety, the changes in Quality of Life and on clinical signs and symptoms of Cushing's disease

2013 Clinical Trials

123. Predictors of Mortality and Long-term Outcomes in Treated Cushing's Disease: A Study of 346 Patients. (PubMed)

Predictors of Mortality and Long-term Outcomes in Treated Cushing's Disease: A Study of 346 Patients. Active Cushing's disease (CD) confers a 4-fold increase in mortality and is associated with significant morbidities. Although excess mortality risk may persist even after CD treatment, predictors of risk in treated CD are not well understood.To identify predictors of mortality, cardiovascular (CV) disease, and recurrence after long-term follow-up among patients with treated CD.A retrospective (...) chart review was conducted to evaluate patients with CD who underwent transsphenoidal adenectomy with a single surgeon.Patients were categorized based on disease response after initial treatment. Cox proportional hazard models identified predictors of mortality, recurrence, and CV outcomes in the overall cohort and each subgroup.Three hundred forty-six subjects were included. Mean age was 39.9 years, and mean duration of follow-up was 6.3 years (range, 1 mo to 30 y). Duration of exposure to excess

Full Text available with Trip Pro

2013 Journal of Clinical Endocrinology and Metabolism

124. Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial. (PubMed)

Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial. A recent phase III randomized controlled trial (NCT00434148) showed efficacy of pasireotide in the treatment of patients with Cushing's disease (CD). Patients were invited to participate in an extension phase of the protocol and a subgroup had a sustained response. We report the experience with 4 patients in our center of which 2 full responders have completed 5.5 and 4.25 years (...) limit of normal had a rapid sustained response to pasireotide and entered the extension phase after 12 months. They remain in clinical and biochemical disease remission and 1 patient now only requires 300 μg daily of pasireotide. All 4 patients developed glucose intolerance; however, the two patients in the extension phase were eventually able to discontinue all diabetes pharmacotherapy. Adverse events included second degree atrioventicular block type 1 without QT prolongation in a patient with pre

2013 Pituitary Controlled trial quality: uncertain

125. Prognostic impact of paraneoplastic cushing's syndrome in small-cell lung cancer. (PubMed)

Prognostic impact of paraneoplastic cushing's syndrome in small-cell lung cancer. Paraneoplastic Cushing's syndrome (CushingPS) in small-cell lung cancer is rare but severe.We studied 383 patients with small-cell lung cancer diagnosed between 1998 and 2012. Among them, 23 patients had CushingPS, 56 had other paraneoplastic syndrome (OtherPS), and 304 had no paraneoplastic syndrome (NoPS).After comparison of the three groups, we observed that CushingPS patients had more extensive disease: 82.6 (...) % versus 67.8% versus 53.3% (p = 0.005), respectively, with more than two metastatic sites: 63.2% versus 15.8% and 24.1% (p ≤ 0.001), a higher World Health Organization performance status (2-4): 73.9% versus 57.1% versus 43.7% (p = 0.006), greater weight loss (≥10%): 47.8% versus 33.9% versus 16.4% (p ≤ 0.001), reduced objective response to first-line treatment: 47.6% versus 74.1% versus 71.1% (p = 0.04), and poorer sensitivity to first-line treatment: 19% versus 38.9% versus 48.6% (p = 0.01). NoPS

Full Text available with Trip Pro

2014 Journal of Thoracic Oncology

126. Maintenance of Response After rTMS for Depression Using tDCS

Maintenance of Response After rTMS for Depression Using tDCS Maintenance of Response After rTMS for Depression Using tDCS - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Maintenance of Response After rTMS (...) for Depression Using tDCS (START) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03708159 Recruitment Status : Recruiting First Posted : October 17, 2018 Last Update Posted : October 17, 2018 See Sponsor: Centre for Addiction

2018 Clinical Trials

127. Diagnostic accuracy and comparison of BIPSS in response to lysine vasopressin and hCRH (PubMed)

Diagnostic accuracy and comparison of BIPSS in response to lysine vasopressin and hCRH Bilateral inferior petrosal sinus sampling (BIPSS) using hCRH is currently considered the 'gold standard' test for the differential diagnosis of ACTH-dependent Cushing's syndrome (CS). Vasopressin is more potent than CRH to stimulate ACTH secretion as shown in animal studies; however, no comparative data of its use are available during BIPSS.To study the diagnostic accuracy and comparison of hCRH and lysine (...) vasopressin (LVP) stimulation during BIPSS.29 patients (27-Cushing's disease, 2-ectopic CS; confirmed on histopathology) underwent BIPSS and were included for the study. Patients were randomized to receive hCRH, 5 U LVP or 10 U LVP during BIPSS for ACTH stimulation. BIPSS and contrast-enhanced magnetic resonance imaging (CEMRI) were compared with intra-operative findings of trans-sphenoidal surgery (TSS) for localization and lateralization of the ACTH source.BIPSS correctly localized the source of ACTH

Full Text available with Trip Pro

2018 Endocrine connections Controlled trial quality: uncertain

128. Efficacy and Neural Mediators of Response to Trauma Management Therapy for PTSD

Efficacy and Neural Mediators of Response to Trauma Management Therapy for PTSD Efficacy and Neural Mediators of Response to Trauma Management Therapy for PTSD - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Efficacy and Neural Mediators of Response to Trauma Management Therapy for PTSD The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03449576 Recruitment Status : Enrolling by invitation First Posted : February 28, 2018 Last Update Posted : January 16, 2019 Sponsor: VA Office of Research and Development

2018 Clinical Trials

129. Androgen Responses to hCG and Ovarian Morphology in PCOS

Androgen Responses to hCG and Ovarian Morphology in PCOS Androgen Responses to hCG and Ovarian Morphology in PCOS - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Androgen Responses to hCG and Ovarian (...) Morphology in PCOS The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03489668 Recruitment Status : Recruiting First Posted : April 5, 2018 Last Update Posted : August 9, 2018 See Sponsor: Poznan University of Medical Sciences

2018 Clinical Trials

130. Regulation of steroidogenesis in a primary pigmented nodular adrenocortical disease-associated adenoma leading to virilization and subclinical Cushing's syndrome. (PubMed)

of steroidogenesis in a case of PPNAD with virilization.A 33-year-old woman presented with primary infertility due to hyperandrogenism. Elevated levels of testosterone and subclinical ACTH-independent Cushing's syndrome led to the discovery of an adrenal tumor, which was diagnosed as PPNAD. In vivo evaluation of aberrantly expressed hormone receptors showed no steroid response to known stimuli. Genetic analysis revealed a PRKAR1A protein-truncating Q28X mutation. After adrenalectomy, steroid levels normalized (...) Regulation of steroidogenesis in a primary pigmented nodular adrenocortical disease-associated adenoma leading to virilization and subclinical Cushing's syndrome. Primary pigmented nodular adrenocortical disease (PPNAD) can lead to steroid hormone overproduction. Mutations in the cAMP protein kinase A regulatory subunit type 1A (PRKAR1A) are causative of PPNAD. Steroidogenesis in PPNAD can be modified through a local glucocorticoid feed-forward loop.Investigation of regulation

Full Text available with Trip Pro

2012 European Journal of Endocrinology

131. Outcome of Cushing's Disease following Transsphenoidal Surgery in a Single Center over 20 Years. (PubMed)

Outcome of Cushing's Disease following Transsphenoidal Surgery in a Single Center over 20 Years. Historically, Cushing's disease (CD) was associated with a 5-yr survival of just 50%. Although advances in CD management have seen mortality rates improve, outcome from transsphenoidal surgery (TSS), the current first-line treatment, varies significantly between centers.The aim of the study was to define outcome including mortality in a cohort of CD patients treated with TSS over 20 yr.We conducted (...) underwent TSS.Patients were subdivided into groups based on disease response after initial treatment. Mortality according to subgroup was also assessed.Median follow-up for clinical data was 4.6 yr. Three outcome groups were identified: cure, 72% (52 of 72); persistent disease, 17% (12 of 72); and disease recurrence, 11% (eight of 72). Median time to recurrence after initial remission was 2.1 yr (interquartile range, 1.3-3.1 yr). Mean follow-up for mortality was 10.9 yr. Thirteen of 80 patients had died

Full Text available with Trip Pro

2012 Journal of Clinical Endocrinology and Metabolism

132. Bronchial Carcinoid Tumors Causing Cushing's Syndrome: More Aggressive Behavior and the Need for Early Diagnosis. (PubMed)

Bronchial Carcinoid Tumors Causing Cushing's Syndrome: More Aggressive Behavior and the Need for Early Diagnosis. The aim of this study was to revisit the characteristics and outcomes of adrenocorticotropin-secreting bronchial carcinoid tumor (BCT) responsible for Cushing's syndrome (CS).We conducted a single-institution retrospective review of 14 patients who underwent pulmonary resection for BCT that presented as CS from October 1993 to November 2011.The group consisted of 8 male patients (57

2012 Annals of Thoracic Surgery

133. An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease

). Please remove one or more studies before adding more. An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. (SEASCAPE) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01582061 Recruitment Status : Completed First Posted : April 20, 2012 Results (...) First Posted : June 19, 2018 Last Update Posted : June 19, 2018 Sponsor: Novartis Pharmaceuticals Information provided by (Responsible Party): Novartis ( Novartis Pharmaceuticals ) Study Details Study Description Go to Brief Summary: This study provided access to pasireotide sc in patients with Cushing's disease.and provided additional information for safety and efficacy of pasireotide s.c. Condition or disease Intervention/treatment Phase Cushing's Disease Drug: Pasireotide sub-cutaneous Phase 3

2012 Clinical Trials

134. Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome

more. Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome (LIPOCUSH) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01688349 Recruitment Status : Completed First Posted : September 19, 2012 Last Update Posted : March 22, 2017 Sponsor: Assistance Publique - Hôpitaux de (...) Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding

2012 Clinical Trials

135. The Postoperative Basal Cortisol and CRH Tests for Prediction of Long-Term Remission from Cushing's Disease after Transsphenoidal Surgery. (PubMed)

The Postoperative Basal Cortisol and CRH Tests for Prediction of Long-Term Remission from Cushing's Disease after Transsphenoidal Surgery. Selective adenomectomy via transsphenoidal surgery induces remission of Cushing's disease (CD) in most patients. Although an undetectable postoperative serum cortisol (<2 μg/dl) has been advocated as an index of remission, there is no consensus on predictors of recurrence.We hypothesized that patients with subnormal cortisol (2-4.9 μg/dl) might achieve long (...) -term remission and that postoperative responses to CRH might predict recurrence.We prospectively studied CD patients with initial remission after adenomectomy or hemihypophysectomy (n = 14). Long-term recurrence (n = 39) or remission (n = 293) was assigned by laboratory results, glucocorticoid dependence, or patient survey at a mean of 10.6 yr after surgery.Postoperatively, morning cortisol was measured on d 3-5, and cortisol and ACTH responses to ovine CRH were assessed around d 10.Follow-up

Full Text available with Trip Pro

2011 Journal of Clinical Endocrinology and Metabolism

136. Cushing and the treatment of brain wounds during World War I. (PubMed)

at the time and eventually, for some, it was Cushing who was responsible for lowering the postoperative mortality rate of brain wounds during World War I. As the decades passed he was eventually credited as the "originator of brain wound care." This report shows that these attributions are misplaced. Cushing merely followed the enlightened surgical precepts of the time developed by Continental (European) surgeons. It also examines Cushing's writings to ascertain how these misperceptions concerning his (...) Cushing and the treatment of brain wounds during World War I. Harvey Cushing, perhaps the most important founder of American neurosurgery, was an Army neurosurgeon in France from 1917 to 1918. Over a 3-month period in 1917 he and his team operated on 133 soldiers with a brain wound. The operative mortality rate for their last 45 patients was 29%, considerably lower than the usual postoperative mortality rate of approximately 50% for those with a brain wound. This accomplishment was lauded

Full Text available with Trip Pro

2011 Journal of Neurosurgery

137. Sequential hormonal changes in 21 patients with recurrent Cushing's disease after successful pituitary surgery. (PubMed)

Sequential hormonal changes in 21 patients with recurrent Cushing's disease after successful pituitary surgery. To describe the sequence of hormonal changes during recurrence of Cushing's disease (CD) after successful transsphenoidal surgery (TSS).Retrospective study in a single center.We studied 101 of the 127 patients treated by TSS for CD between 1996 and 2009, who had hypocortisolism or eucortisolism for at least 3 months post-TSS. We arbitrarily defined 'overt recurrence', as presence (...) , median 43, range 7-94 vs mean 21.5 months, median 17, range 3-61, P=0.05), in patients with early post-TSS hypocortisolism compared with those with eucortisolism. Increase in midnight cortisol occurred in a mean time of 38.2 months, while UC elevation was observed at 50.6 months. Vasopressin analogs and CRH tests were eventually positive in 85 and 93% of all patients respectively; a positive response to one of the two dynamic tests preceded the increase in midnight cortisol or UC in 71 and 64

Full Text available with Trip Pro

2011 European Journal of Endocrinology

138. Endogenous ACTH Concentration-Cortisol Secretion Dose Analysis Unmasks Decreased ACTH Potency in Cushing's Disease with Restoration after Successful Pituitary Adenomectomy. (PubMed)

· min, vs. controls, 21 ± 2.3 nmol/liter · min (P <0.0001), and cured patients, 15 ± 3.2 nmol/liter · min (NS vs. controls)]. Sensitivity to endogenous ACTH did not differ among the three groups.The adrenal gland in Cushing's disease exhibits decreased responsiveness to submaximal ACTH drive and amplified efficacy, with unchanged sensitivity. These target-gland abnormalities are reversible in long-term remission after pituitary surgery. (...) Endogenous ACTH Concentration-Cortisol Secretion Dose Analysis Unmasks Decreased ACTH Potency in Cushing's Disease with Restoration after Successful Pituitary Adenomectomy. The relationship between circulating ACTH levels and cortisol secretion in Cushing's disease is not precisely known.Chronic ACTH hyperstimulation leads to decreased adrenal potency and is restored after normalization of ACTH secretion.Subjects included 20 patients with Cushing's disease, eight patients in long-term remission

Full Text available with Trip Pro

2011 Journal of Clinical Endocrinology and Metabolism

139. Long-term Beneficial Metabolic Effects of Adrenalectomy in Subclinical Cushing's Syndrome of Adrenal Incidentaloma

of saved studies (100). Please remove one or more studies before adding more. Long-term Beneficial Metabolic Effects of Adrenalectomy in Subclinical Cushing's Syndrome of Adrenal Incidentaloma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details (...) . ClinicalTrials.gov Identifier: NCT01382420 Recruitment Status : Recruiting First Posted : June 27, 2011 Last Update Posted : April 4, 2019 See Sponsor: Samsung Medical Center Collaborators: Asan Medical Center Severance Hospital Konkuk University Medical Center Information provided by (Responsible Party): Jae Hyeon Kim, Samsung Medical Center Study Details Study Description Go to Brief Summary: Objective: To determine the metabolic effects of the adrenalectomy in subclinical Cushing's syndrome of adrenal

2011 Clinical Trials

140. Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

studies before adding more. Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01374906 Recruitment Status : Completed First Posted : June 16, 2011 Results First Posted : April 11, 2018 Last Update Posted : May 22 (...) , 2018 Sponsor: Novartis Pharmaceuticals Information provided by (Responsible Party): Novartis ( Novartis Pharmaceuticals ) Study Details Study Description Go to Brief Summary: This is a randomized, double-blind, multicenter, phase III study to evaluate the safety and efficacy of 2 dosing regiments of Pasireotide long acting release (LAR) in patients with Cushing's disease. Condition or disease Intervention/treatment Phase Cushing's Disease Drug: pasireotide LAR Drug: SOM230 LAR 30 mg Drug: SOM230

2011 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>